Please wait while the formulary information is being retrieved.
XERESE (ACYCLOVIR/HYDROCORTISONE)
- Recurrent herpes simplex labialis
5 %-1 % topical cream
- Apply to the affected area(s) by topical route 5 times per day
Recurrent herpes simplex labialis
- Apply to the affected area(s) by topical route 5 times per day
- Apply to the affected area(s) by topical route 5 times per day for 5 days
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- None
Severe
Moderate
- Hypothalamic-pituitary insufficiency
- No disease contraindications
XERESE (ACYCLOVIR/HYDROCORTISONE)
- Recurrent herpes simplex labialis
- None
- Abnormal desquamation
- Dry skin
- Erythema
- Skin irritation
- Stinging of skin
More Frequent
Severe
Less Severe
- Folliculitis
- Purpura
- Skin and skin structure infection
- Skin atrophy
- Cheilosis
- Headache disorder
- Paresthesia
- Pruritus of skin
- Skin rash
- Telangiectasia
- Treatment site sequelae
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Adrenal cortical insufficiency
- Anaphylaxis
- Angioedema
- Bullous dermatitis
- Cataracts
- Central serous chorioretinopathy
- Glaucoma
- Hypothalamic-pituitary insufficiency
- Ocular hypertension
- Skin hypopigmentation
- Skin striae
- Skin ulcer
- Urticaria
Less Severe
- Acneiform eruption
- Alopecia
- Blistering skin
- Contact dermatitis
- Dry skin
- Dyschromia
- Eczema
- Glycosuria
- Hirsutism
- Hypercortisolism
- Hyperesthesia
- Hyperglycemia
- Miliaria
- Perioral dermatitis
- Skin irritation
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Acyclovir (Topical)
Safety and efficacy not established age < 6 years.
Prolonged or extensive use may lead to systemic absorption; may affect growth rate.
- 1 Day – 6 Years
- Safety and efficacy not established age < 6 years.
- 1 Day – 18 Years
- Safety and efficacy not established age < 6 years.
Hydrocortisone (Top,Ophth,Rect)
Safety and efficacy not established age < 6 years.
Prolonged or extensive use may lead to systemic absorption; may affect growth rate.
- 1 Day – 6 Years
- Prolonged or extensive use may lead to systemic absorption; may affect growth rate.
- 1 Day – 18 Years
- Prolonged or extensive use may lead to systemic absorption; may affect growth rate.
Acyclovir
- Severity Level:
B
- Additional Notes:
Hydrocortisone (topical, Non-systemic)
- Severity Level:
2
- Additional Notes: Systemic absorption unknown; insuff human data
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
Acyclovir (topical, Buccal)
Unlikely to be excreted since dose is small & systemic absorption is minimal
Insufficient data available; limited use may pose little risk
| General | Excretion Potential | Effect on Infant | Notes |
| No known risks; does not adversely affect lactation | Unknown | No adverse effect | Unlikely to be excreted since dose is small & systemic absorption is minimal |
Hydrocortisone (top., Rectal)
Unlikely to be excreted since dose is small & systemic absorption is minimal
Insufficient data available; limited use may pose little risk
| General | Excretion Potential | Effect on Infant | Notes |
| No known risks; does not adversely affect lactation | Unknown | Not known; no or inclusive data | Insufficient data available; limited use may pose little risk |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Recurrent herpes simplex labialis | |
| B00.9 | Herpesviral infection, unspecified |
| 0-9 | A-Z |
|---|---|
| B00.9 | Herpesviral infection, unspecified |
Formulary Reference Tool